Clinical Trial Update: SLV308 for Treatment of Patients With Early Parkinson's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial of SLV308 for early Parkinson's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• SLV308

Snippet

Sponsor: Solvay Pharmaceuticals | Conditions: Early Stage Parkinson's Disease | Phase 3 | Status: COMPLETED